BeneFIX® , Coagulation Factor IX (Recombinant), is a purified protein produced by recombinant DNA technology for use in therapy of factor IX deficiency, known as hemophilia B or Christmas disease. Coagulation Factor IX (Recombinant) is a glycoprotein with an approximate molecular mass of 55,000 Da consisting of 415 amino acids in a single chain. It has a primary amino acid sequence that is identical to the Ala148 allelic form of plasma-derived factor IX, and has structural and functional characteristics similar to those of endogenous factor IX.
BeneFIX® , Coagulation Factor IX (Recombinant), is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings.
BeneFIX® , Coagulation Factor IX (Recombinant), is not indicated for the treatment of other factor deficiencies (e.g., factors II, VII, VIII, and X), nor for the treatment of hemophilia A patients with inhibitors to factor VIII, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.
Media Articles Related to Benefix (Coagulation Factor IX)
FDA approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B
Source: Blood / Hematology News From Medical News Today [2014.04.01]
The U.S. Food and Drug Administration has approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B.
Published Studies Related to Benefix (Coagulation Factor IX)
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. [2011.02]
Anticoagulants are the cornerstone of current acute coronary syndrome (ACS) therapy; however, anticoagulation regimens that aggressively reduce ischemic events are almost uniformly associated with more bleeding... The objectives of RADAR are (1) to determine the safety of a range of levels of RB006 reversal with RB007 after catheterization, (2) to confirm whether a dose of 1 mg/kg RB006 results in near-complete inhibition of factor IXa in patients with ACS, and (3) to assess the efficacy of RB006 as an anticoagulant in patients with ACS undergoing percutaneous coronary intervention.
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. [2010.08.10]
CONCLUSIONS: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation. CLINICAL TRIAL REGISTRATION:URL: http://www.clinicaltrials.gov. Unique identifier: NCT00715455.
Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. [2010.04.30]
AIM: To examine whether plasma levels of coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin are associated with coronary heart disease (CHD) in a prospective case-cohort study... CONCLUSIONS: Positive associations of factors IX and XI, and alpha-2 antiplasmin with incident CHD were not strong and accounted for by classical coronary risk factors.
Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. [2009.10.01]
Higher levels of procoagulant factors and factor XII deficiency may be risk factors for first venous thromboembolism (VTE). We studied associations of coagulation factors IX through XIII with risk of future VTE in 2 general population samples... Among these procoagulant factors, only elevated factor XI was a risk factor for VTE.
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. [2002.02]
Compared to second generation, the use of third generation oral contraceptives has been associated with an increased risk of venous thrombosis especially in women with the factor V Leiden mutation. To find an explanation for these risk differences we investigated the effects of desogestrel- and levonorgestrel-containing oral contraceptives as well as their progestagens separately on the coagulation system in the absence or presence of the factor V Leiden mutation...
Clinical Trials Related to Benefix (Coagulation Factor IX)
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B [Completed]
To assess efficacy and safety of BeneFix® for prophylaxis in "Short-term" therapy and on
demand therapy for all bleeding episodes of subjects with hemophilia B.
Study Evaluating rFIX; BeneFIX in Severe Hemophilia B [Completed]
To characterize the safety and efficacy of rFIX in children less than 6 years of age with
severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery.
This study will provide an opportunity for systematic observation of treatment with rFIX in
children less than 6 years of age regardless of prior FIX treatment. Younger patients
exhibit a different pharmacokinetic profile and therefore may respond differently to rFIX
infusions when compared with older children and adults. This evaluation will provide data
from which recommendations can be made regarding rFIX dosing and treatment of these patients.
Surveillance for certain observations that have been made in patients treated with rFIX in
the clinical and postmarketing setting will be performed, including inhibitor development,
thrombogenicity, FIX recovery/lack of effect, allergic-type manifestations, and RBC
agglutination. Comparisons will be derived from published reports and communications
describing experience with other FIX products and protein therapeutics in general.
Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) [Completed]
In this postmarketing study, the safety of Nonafact® (human coagulation factor IX) is
evaluated in previous treated and untreated patients with severe, moderate or mild
Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B [Terminated]
In this study a modified virus called adeno-associated virus (AAV) will be used to transfer a
normal gene for human clotting factor IX into patients with severe hemophilia B (AAV human
Factor IX vector). Gene therapy is a very new medical technique being used in a number of
clinical studies for diseases such as cancer and cystic fibrosis. At this time, the U. S.
Food and Drug Administration has approved no gene transfer products for commercial use. To
date, 8 subjects have received AAV vector in the muscle for a hemophilia B trial by
intramuscular injection, and, to date, 6 subjects have been treated with AAV vector in the
current hemophilia B liver trial. Eleven cystic fibrosis subjects have received AAV vector
into their nasal sinuses or lungs to date. In this study, AAV human Factor IX vector will
be injected into the liver using a catheter inserted into a large blood vessel (called the
proper hepatic artery or the right hepatic artery).
Study Evaluating On-Demand Treatment With BeneFIX in Chinese Subjects [Recruiting]
This study will evaluate the safety and efficacy of on-demand treatment with BeneFIX in
Chinese hemophilia B subjects
Reports of Suspected Benefix (Coagulation Factor IX) Side Effects
Factor IX Inhibition (11),
Drug Ineffective (8),
Anaphylactic Reaction (8),
Rash Pruritic (5), more >>
Page last updated: 2014-04-01